Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
FLT3 tyrosine-kinase inhibitor

Quizartinib (Specialist drug)

Brand names: Vanflyta

Quizartinib is an oral FLT3 tyrosine kinase inhibitor used as a specialist treatment for FLT3-ITD-positive acute myeloid leukaemia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits the FLT3 receptor tyrosine kinase, blocking constitutive signalling driven by FLT3 internal tandem duplication mutations and thereby suppressing leukaemic cell proliferation.

Prescribing in practice

  • It prolongs the QT interval and has been associated with serious ventricular arrhythmia, so baseline and periodic ECG and correction of electrolytes are essential before and during treatment.
  • Treatment is restricted to specialist haemato-oncology services and patients should be confirmed FLT3-ITD positive by a validated assay before starting.
  • Numerous CYP3A4 interactions are relevant and concomitant strong inhibitors require dose review per current prescribing references.

Monitoring

Monitor ECG (QTc), serum electrolytes including potassium and magnesium, and full blood count throughout treatment.

Counselling the patient

  • Report fainting, palpitations or an irregular heartbeat promptly.
  • Tell the team about all other medicines, as several can dangerously affect heart rhythm.
  • Attend all blood test and ECG appointments.

Evidence & guidelines

Use is guided by the SPC and specialist haemato-oncology protocols for FLT3-mutated AML.

Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways